Brett Ley1, Jeffrey Swigris2, Bann-Mo Day3, John L Stauffer3, Karina Raimundo3, Willis Chou3, Harold R Collard1. 1. 1 Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California. 2. 2 Interstitial Lung Disease Program, Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colorado; and. 3. 3 Genentech, Inc., South San Francisco, California.
Abstract
RATIONALE: Respiratory-related hospitalizations of patients with idiopathic pulmonary fibrosis (IPF) are more frequent than those for acute IPF exacerbations and are associated with poor outcomes. OBJECTIVES: To compare the risk of nonelective hospitalization by type (all-cause, respiratory related, and non-respiratory related) and death after hospitalization with use of pirfenidone versus placebo over 52 weeks using data derived from three phase III IPF clinical trials. METHODS: Individual patient data was pooled from three phase III randomized, placebo-controlled studies of pirfenidone for IPF (the two CAPACITY [Clinical Studies Assessing Pirfenidone in IPF: Research of Efficacy and Safety Outcomes] trials and the ASCEND [Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis] trial), including all patients randomized to pirfenidone 2,403 mg/d (n = 623) or placebo (n = 624). The risk of hospitalization over 52 weeks was compared using standard time-to-event methods. Among those hospitalized, the risk of death after hospitalization was compared with adjustment for treatment group propensity. MEASUREMENTS AND MAIN RESULTS: A total of 1,247 patients (692 from the CAPACITY trials and 555 from the ASCEND trial) were included in the pooled analysis. Pirfenidone was associated with lower risk of respiratory-related hospitalization than placebo (7% vs. 12%; hazard ratio [HR], 0.52; 95% confidence interval [CI], 0.36-0.77; P = 0.001), but all-cause (HR, 0.91; 95% CI, 0.70-1.19; P = 0.528) or non-respiratory-related hospitalization (HR, 1.32; 95% CI, 0.92-1.88; P = 0.145) was not. Among those hospitalized for any reason, treatment with pirfenidone was associated with lower risk of death after hospitalization up to 52 weeks after randomization, but this association was no longer significant with longer follow-up. CONCLUSIONS: In a pooled analysis of three phase III IPF clinical trials, patients receiving pirfenidone had a lower risk of nonelective respiratory-related hospitalization over the course of 1 year. The effect of pirfenidone on death after hospitalization is uncertain.
RCT Entities:
RATIONALE: Respiratory-related hospitalizations of patients with idiopathic pulmonary fibrosis (IPF) are more frequent than those for acute IPF exacerbations and are associated with poor outcomes. OBJECTIVES: To compare the risk of nonelective hospitalization by type (all-cause, respiratory related, and non-respiratory related) and death after hospitalization with use of pirfenidone versus placebo over 52 weeks using data derived from three phase III IPF clinical trials. METHODS: Individual patient data was pooled from three phase III randomized, placebo-controlled studies of pirfenidone for IPF (the two CAPACITY [Clinical Studies Assessing Pirfenidone in IPF: Research of Efficacy and Safety Outcomes] trials and the ASCEND [Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis] trial), including all patients randomized to pirfenidone 2,403 mg/d (n = 623) or placebo (n = 624). The risk of hospitalization over 52 weeks was compared using standard time-to-event methods. Among those hospitalized, the risk of death after hospitalization was compared with adjustment for treatment group propensity. MEASUREMENTS AND MAIN RESULTS: A total of 1,247 patients (692 from the CAPACITY trials and 555 from the ASCEND trial) were included in the pooled analysis. Pirfenidone was associated with lower risk of respiratory-related hospitalization than placebo (7% vs. 12%; hazard ratio [HR], 0.52; 95% confidence interval [CI], 0.36-0.77; P = 0.001), but all-cause (HR, 0.91; 95% CI, 0.70-1.19; P = 0.528) or non-respiratory-related hospitalization (HR, 1.32; 95% CI, 0.92-1.88; P = 0.145) was not. Among those hospitalized for any reason, treatment with pirfenidone was associated with lower risk of death after hospitalization up to 52 weeks after randomization, but this association was no longer significant with longer follow-up. CONCLUSIONS: In a pooled analysis of three phase III IPF clinical trials, patients receiving pirfenidone had a lower risk of nonelective respiratory-related hospitalization over the course of 1 year. The effect of pirfenidone on death after hospitalization is uncertain.
Authors: Roland M du Bois; Derek Weycker; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Alex Kartashov; Lisa Lancaster; Paul W Noble; Ganesh Raghu; Steven A Sahn; Javier Szwarcberg; Michiel Thomeer; Dominique Valeyre; Talmadge E King Journal: Am J Respir Crit Care Med Date: 2011-08-15 Impact factor: 21.405
Authors: Steven D Nathan; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Ian Glaspole; Marilyn K Glassberg; David R Kardatzke; Monica Daigl; Klaus-Uwe Kirchgaessler; Lisa H Lancaster; David J Lederer; Carlos A Pereira; Jeffrey J Swigris; Dominique Valeyre; Paul W Noble Journal: Lancet Respir Med Date: 2016-11-19 Impact factor: 30.700
Authors: Michael T Durheim; Harold R Collard; Rhonda S Roberts; Kevin K Brown; Kevin R Flaherty; Talmadge E King; Scott M Palmer; Ganesh Raghu; Laurie D Snyder; Kevin J Anstrom; Fernando J Martinez Journal: Lancet Respir Med Date: 2015-04-15 Impact factor: 30.700
Authors: Brett Ley; Williamson Z Bradford; Eric Vittinghoff; Derek Weycker; Roland M du Bois; Harold R Collard Journal: Am J Respir Crit Care Med Date: 2016-09-15 Impact factor: 21.405
Authors: Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble Journal: N Engl J Med Date: 2014-05-18 Impact factor: 91.245
Authors: Paul W Noble; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Roland M du Bois; Elizabeth A Fagan; Robert S Fishman; Ian Glaspole; Marilyn K Glassberg; Lisa Lancaster; David J Lederer; Jonathan A Leff; Steven D Nathan; Carlos A Pereira; Jeffrey J Swigris; Dominique Valeyre; Talmadge E King Journal: Eur Respir J Date: 2015-12-02 Impact factor: 16.671
Authors: Michael Kadoch; Aleksandar Kitich; Shehabaldin Alqalyoobi; Elyse Lafond; Elena Foster; Maya Juarez; Cesar Mendez; Thomas W Smith; Garrett Wong; Walter D Boyd; Jeffrey Southard; Justin M Oldham Journal: Respir Med Date: 2018-02-27 Impact factor: 3.415
Authors: Arantza Campo; José María González-Ruiz; Enrique Andreu; Ana B Alcaide; María M Ocón; Juan De-Torres; Jesús Pueyo; Rosa Cordovilla; Eva Villaron; Fermín Sanchez-Guijo; Miguel Barrueco; Jorge Nuñez-Córdoba; Felipe Prósper; Javier J Zulueta Journal: ERJ Open Res Date: 2021-06-28